KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Non Operating Income (2016 - 2025)

BeOne Medicines (ONC) has disclosed Non Operating Income for 10 consecutive years, with -$35.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 159.87% to -$35.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$42.6 million, a 236.71% decrease, with the full-year FY2025 number at -$42.6 million, down 236.71% from a year prior.
  • Non Operating Income was -$35.7 million for Q4 2025 at BeOne Medicines, down from -$19.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $336.7 million in Q3 2023 to a low of -$930.0 million in Q4 2022.
  • A 5-year average of -$115.0 million and a median of -$8.1 million in 2021 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: skyrocketed 451.16% in 2021, then plummeted 14850.06% in 2022.
  • BeOne Medicines' Non Operating Income stood at -$800.2 million in 2021, then decreased by 16.23% to -$930.0 million in 2022, then soared by 36.67% to -$589.0 million in 2023, then skyrocketed by 97.67% to -$13.7 million in 2024, then tumbled by 159.87% to -$35.7 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Non Operating Income are -$35.7 million (Q4 2025), -$19.0 million (Q3 2025), and $8.2 million (Q2 2025).